8-K: PACS Group Secures NYSE Extension, Reports Strong H1 2025 Metrics

PACS Group, Inc. received a NYSE listing extension until November 19, 2025, to complete financial restatements, while announcing preliminary record revenue and Adjusted EBITDA for the first half of 2025.

Summary

• Received an extension from the New York Stock Exchange (NYSE) until November 19, 2025, to complete the restatement of financial statements for Q1 2024 and Q2 2024, and become current with SEC filing obligations.
• Expects to report record revenue and Adjusted EBITDA for the first six months of 2025 upon becoming current with SEC filings.
• Grew its portfolio by a net addition of 96 healthcare facilities since the second quarter of 2024, with the majority occurring in the second half of 2024.
• As of June 30, 2025, subsidiaries operated 316 healthcare facilities with 32,208 skilled nursing beds and 2,419 assisted living beds across 17 states.
• Reported preliminary total facilities occupancy of 88.9% for the first half of 2025, significantly above an industry average of 78.0%.
• Cash and cash equivalents increased to $294.2 million as of June 30, 2025, from $157.7 million as of December 31, 2024.
• Appointed Mark Hancock as interim Chief Financial Officer, effective September 3, 2025, succeeding Derick Apt.
• Undertook an intense review of its regulatory compliance program, including retaining a new interim Chief Compliance Officer, Kathy Lauer.

Sentiment

Score: 7

Explanation: The sentiment is cautiously positive. While the company faces significant compliance and reporting issues requiring a NYSE extension and financial restatements, its preliminary operational and financial metrics (record revenue/EBITDA, high occupancy, strong cash growth, facility expansion) indicate robust underlying business performance. The proactive steps in compliance and management changes also contribute positively, but the unresolved investigations and restatements remain a notable concern.

Positives

• Anticipates record revenue and Adjusted EBITDA for the first six months of 2025 upon becoming current with SEC filings.
• Achieved a total facilities occupancy of 88.9% for H1 2025, significantly higher than the industry average of 78.0%.
• Mature facilities demonstrated strong occupancy at 95.1% and a skilled mix of 34.1%.
• Expanded its portfolio by a net addition of 96 healthcare facilities since Q2 2024, reaching 316 facilities across 17 states.
• Maintained a strong cash position with $294.2 million in cash and cash equivalents as of June 30, 2025, nearly doubling from December 31, 2024.
• 179 facilities, representing 64.6% of its skilled nursing portfolio, achieved a 4 or 5 star CMS QM rating.
• Maintained strong employee retention levels and commitment to its mission of revolutionizing post-acute care.

Negatives

• Failed to comply with NYSE listing standards, necessitating an extension due to delayed financial statements and SEC filings.
• Requires restatement of financial statements for the three months ended March 31, 2024, and the three and six months ended June 30, 2024.
• Ongoing independent Audit Committee investigation and government investigations are noted.
• The preliminary financial results are unaudited and subject to change, with no reconciliation of Adjusted EBITDA to GAAP net income provided due to insufficient information.

Risks

• Outcome of any ongoing government or internal investigations.
• Risks associated with litigation.
• Ability to restate prior financial statements and file delinquent quarterly and annual reports within the NYSE's granted additional period (November 19, 2025).
• Risks associated with the NYSE's ongoing compliance monitoring.
• Preliminary financial and operating metrics may differ from actual results upon completion of management's final review and the company's other closing procedures.

Future Outlook

Expects to report record revenue and Adjusted EBITDA for the first six months of 2025 upon becoming current with SEC filings. The company intends to continue utilizing its cash to fuel growth and execute its business plan, capitalizing on opportunities to accelerate growth and drive value creation for all stakeholders. It is also implementing additional measures to enhance processes and controls surrounding regulatory compliance.

Management Comments

• "We have been fully cooperating with the independent Audit Committee's ongoing independent investigation and working diligently to restate our prior financial statements and become current with our financial reporting obligations, which we intend to do within the NYSE timeline." Jason Murray, CEO.
• "At the same time, we have been executing on our business objectives and delivering on our focused growth strategy. PACS today is benefiting from solid business momentum, and we are in a strong financial and operational position supported by a growing portfolio of high-quality facilities and a solid balance sheet." Jason Murray, CEO.
• "I am deeply impressed by the urgency and commitment of the PACS team in its efforts to enhance compliance processes for the Company's current phase of growth and development. I am confident that the PACS team is taking the right steps to best position the Company for the benefit of all stakeholders." Kathy Lauer, Interim Chief Compliance Officer.
• "As Executive Vice Chairman, I've been closely involved with oversight of the Company's strategic growth plans, and I'm encouraged to see continued momentum across the organization. I've been actively working with the Audit Committee and the management team to become current with our SEC filings and complete the restatement of our prior financial statements, and I look forward to continuing to support our facilities in delivering excellence in clinical quality and patient care." Mark Hancock, Interim CFO.

Industry Context

The post-acute care and senior living industry is experiencing ongoing demand, which PACS Group is capitalizing on through strategic acquisitions and operational efficiency. The company's high occupancy rates and growth in facility count reflect a strong market position. However, the increased regulatory scrutiny and compliance challenges, as evidenced by the need for financial restatements and enhanced compliance programs, are common themes in highly regulated healthcare sectors, emphasizing the importance of robust governance and reporting.

Comparison to Industry Standards

• Total facilities occupancy of 88.9% significantly exceeds the industry average of 78.0%, indicating strong operational performance and demand for services.
• The company's growth through the net addition of 96 healthcare facilities since Q2 2024 demonstrates an aggressive expansion strategy, potentially outpacing many competitors in terms of portfolio growth.
• The achievement of 4 or 5 star CMS QM ratings for 64.6% of its skilled nursing portfolio suggests a commitment to quality care that likely compares favorably to industry benchmarks, though specific competitor data is not provided.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing independent Audit Committee investigation.
• Ongoing government investigations.

Stakeholder Impact

• Shareholders: Potential for increased value from strong operational performance and growth, but also uncertainty and risk due to delayed filings, restatements, and ongoing investigations. NYSE compliance is critical for liquidity.
• Employees: Strong employee retention levels suggest a stable work environment despite corporate challenges.
• Customers/Patients: Continued focus on delivering excellence in clinical quality and patient care, supported by high CMS QM ratings and occupancy.
• Creditors: Strong cash position and expected record financial performance could reassure creditors, but the compliance issues might raise concerns.
• Regulatory Authorities: Under scrutiny from NYSE and government investigations, requiring diligent compliance and reporting.

Next Steps

• Complete the restatement of financial statements for Q1 2024 and Q2 2024.
• Become current with SEC filing obligations by November 19, 2025, to regain NYSE compliance.
• Continue to utilize cash to fuel growth and execute its business plan.
• Complete the Audit Committee's independent investigation.
• Implement additional measures to enhance processes and controls surrounding regulatory compliance.

Key Dates

Recommendation

While PACS Group demonstrates strong operational momentum with record preliminary revenue and Adjusted EBITDA, high occupancy rates, and significant facility expansion, the ongoing issues with financial restatements, delayed SEC filings, and associated NYSE compliance risks, coupled with government and internal investigations, introduce considerable uncertainty. The appointment of an interim CFO and CCO, along with a commitment to enhance compliance, are positive steps. However, until the financial statements are restated, filings are current, and investigations are resolved, the stock carries elevated risk. A 'hold' recommendation allows investors to maintain their position while awaiting clarity on these critical governance and reporting issues, balancing the strong operational performance against the significant compliance overhang.

Keywords

PACS Group, NYSE, Listing Extension, Financial Restatement, Operating Metrics, Healthcare Facilities, Skilled Nursing, Assisted Living, Adjusted EBITDA, Occupancy Rate, Compliance Program, CFO Appointment, Post-Acute Care, SEC Filings